Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting

A randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment

Naoki Yoshinaga, Tomihisa Niitsu, Hideki Hanaoka, Yasunori Sato, Fumiyo Ohshima, Satoshi Matsuki, Osamu Kobori, Michiko Nakazato, Akiko Nakagawa, Masaomi Iyo, Eiji Shimizu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: Pharmacotherapy and cognitive behavioural therapy (CBT) are consistently effective as first-line treatments for social anxiety disorders (SADs). Nevertheless, pharmacotherapy is often the first choice in clinical practice. In many countries, the first line of pharmacotherapy involves the administration of a selective serotonin reuptake inhibitor (SSRI). Although a significant proportion of patients with SAD fail to respond to the initial SSRI administration, there is no standard approach to the management of SSRI-resistant SAD. This paper describes the study protocol for a randomised controlled trial to evaluate the clinical effectiveness of CBT as a next-step strategy, concomitant with conventional treatment, for patients with SSRI-resistant SAD. Methods and analysis: This Prospective Randomized Open Blinded End-point study is designed with two parallel groups, with dynamic allocation at the individual level. The interventions for the two groups are conventional treatment, alone, and CBT combined with conventional treatment, for 16 weeks. The primary endpoint of SAD severity will be assessed by an independent assessor using the Liebowitz Social Anxiety Scale, and secondary end-points include severity of other social anxieties, depressive severity and functional impairment. All measures will be assessed at weeks 0 (baseline), 8 (halfway point) and 16 (postintervention) and the outcomes will be analysed based on the intent-to-treat. Statistical analyses are planned for the study design stage so that field materials can be appropriately designed.

Original languageEnglish
Article number002242
JournalBMJ open
Volume3
Issue number2
DOIs
Publication statusPublished - 2013 Mar 20
Externally publishedYes

Fingerprint

Serotonin Uptake Inhibitors
Cognitive Therapy
Clinical Protocols
Randomized Controlled Trials
Drug Therapy
Anxiety
Therapeutics
Social Phobia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting : A randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment. / Yoshinaga, Naoki; Niitsu, Tomihisa; Hanaoka, Hideki; Sato, Yasunori; Ohshima, Fumiyo; Matsuki, Satoshi; Kobori, Osamu; Nakazato, Michiko; Nakagawa, Akiko; Iyo, Masaomi; Shimizu, Eiji.

In: BMJ open, Vol. 3, No. 2, 002242, 20.03.2013.

Research output: Contribution to journalArticle

Yoshinaga, Naoki ; Niitsu, Tomihisa ; Hanaoka, Hideki ; Sato, Yasunori ; Ohshima, Fumiyo ; Matsuki, Satoshi ; Kobori, Osamu ; Nakazato, Michiko ; Nakagawa, Akiko ; Iyo, Masaomi ; Shimizu, Eiji. / Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting : A randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment. In: BMJ open. 2013 ; Vol. 3, No. 2.
@article{8be99de110ea4ecc97bd9839e2c700b2,
title = "Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting: A randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment",
abstract = "Introduction: Pharmacotherapy and cognitive behavioural therapy (CBT) are consistently effective as first-line treatments for social anxiety disorders (SADs). Nevertheless, pharmacotherapy is often the first choice in clinical practice. In many countries, the first line of pharmacotherapy involves the administration of a selective serotonin reuptake inhibitor (SSRI). Although a significant proportion of patients with SAD fail to respond to the initial SSRI administration, there is no standard approach to the management of SSRI-resistant SAD. This paper describes the study protocol for a randomised controlled trial to evaluate the clinical effectiveness of CBT as a next-step strategy, concomitant with conventional treatment, for patients with SSRI-resistant SAD. Methods and analysis: This Prospective Randomized Open Blinded End-point study is designed with two parallel groups, with dynamic allocation at the individual level. The interventions for the two groups are conventional treatment, alone, and CBT combined with conventional treatment, for 16 weeks. The primary endpoint of SAD severity will be assessed by an independent assessor using the Liebowitz Social Anxiety Scale, and secondary end-points include severity of other social anxieties, depressive severity and functional impairment. All measures will be assessed at weeks 0 (baseline), 8 (halfway point) and 16 (postintervention) and the outcomes will be analysed based on the intent-to-treat. Statistical analyses are planned for the study design stage so that field materials can be appropriately designed.",
author = "Naoki Yoshinaga and Tomihisa Niitsu and Hideki Hanaoka and Yasunori Sato and Fumiyo Ohshima and Satoshi Matsuki and Osamu Kobori and Michiko Nakazato and Akiko Nakagawa and Masaomi Iyo and Eiji Shimizu",
year = "2013",
month = "3",
day = "20",
doi = "10.1136/bmjopen-2012-002242",
language = "English",
volume = "3",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting

T2 - A randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment

AU - Yoshinaga, Naoki

AU - Niitsu, Tomihisa

AU - Hanaoka, Hideki

AU - Sato, Yasunori

AU - Ohshima, Fumiyo

AU - Matsuki, Satoshi

AU - Kobori, Osamu

AU - Nakazato, Michiko

AU - Nakagawa, Akiko

AU - Iyo, Masaomi

AU - Shimizu, Eiji

PY - 2013/3/20

Y1 - 2013/3/20

N2 - Introduction: Pharmacotherapy and cognitive behavioural therapy (CBT) are consistently effective as first-line treatments for social anxiety disorders (SADs). Nevertheless, pharmacotherapy is often the first choice in clinical practice. In many countries, the first line of pharmacotherapy involves the administration of a selective serotonin reuptake inhibitor (SSRI). Although a significant proportion of patients with SAD fail to respond to the initial SSRI administration, there is no standard approach to the management of SSRI-resistant SAD. This paper describes the study protocol for a randomised controlled trial to evaluate the clinical effectiveness of CBT as a next-step strategy, concomitant with conventional treatment, for patients with SSRI-resistant SAD. Methods and analysis: This Prospective Randomized Open Blinded End-point study is designed with two parallel groups, with dynamic allocation at the individual level. The interventions for the two groups are conventional treatment, alone, and CBT combined with conventional treatment, for 16 weeks. The primary endpoint of SAD severity will be assessed by an independent assessor using the Liebowitz Social Anxiety Scale, and secondary end-points include severity of other social anxieties, depressive severity and functional impairment. All measures will be assessed at weeks 0 (baseline), 8 (halfway point) and 16 (postintervention) and the outcomes will be analysed based on the intent-to-treat. Statistical analyses are planned for the study design stage so that field materials can be appropriately designed.

AB - Introduction: Pharmacotherapy and cognitive behavioural therapy (CBT) are consistently effective as first-line treatments for social anxiety disorders (SADs). Nevertheless, pharmacotherapy is often the first choice in clinical practice. In many countries, the first line of pharmacotherapy involves the administration of a selective serotonin reuptake inhibitor (SSRI). Although a significant proportion of patients with SAD fail to respond to the initial SSRI administration, there is no standard approach to the management of SSRI-resistant SAD. This paper describes the study protocol for a randomised controlled trial to evaluate the clinical effectiveness of CBT as a next-step strategy, concomitant with conventional treatment, for patients with SSRI-resistant SAD. Methods and analysis: This Prospective Randomized Open Blinded End-point study is designed with two parallel groups, with dynamic allocation at the individual level. The interventions for the two groups are conventional treatment, alone, and CBT combined with conventional treatment, for 16 weeks. The primary endpoint of SAD severity will be assessed by an independent assessor using the Liebowitz Social Anxiety Scale, and secondary end-points include severity of other social anxieties, depressive severity and functional impairment. All measures will be assessed at weeks 0 (baseline), 8 (halfway point) and 16 (postintervention) and the outcomes will be analysed based on the intent-to-treat. Statistical analyses are planned for the study design stage so that field materials can be appropriately designed.

UR - http://www.scopus.com/inward/record.url?scp=84875031689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875031689&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2012-002242

DO - 10.1136/bmjopen-2012-002242

M3 - Article

VL - 3

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 2

M1 - 002242

ER -